High-dose i.v. granisetron for the prevention of chemotherapy-induced emesis: cardiac safety and tolerability.


This phase II trial assessed the cardiovascular safety and tolerability of high-dose granisetron for the treatment of nausea and vomiting in cancer patients undergoing emetogenic chemotherapy. Forty-one patients were given 30-min infusions of granisetron, 40 or 120 microg/kg i.v., as either a single dose or as split doses, at 6-h intervals. Subsequently… (More)


  • Presentations referencing similar topics